KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Raw Materials (2018 - 2025)

Historic Raw Materials for Alnylam Pharmaceuticals (ALNY) over the last 8 years, with Q3 2025 value amounting to $22.3 million.

  • Alnylam Pharmaceuticals' Raw Materials fell 50.97% to $22.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.3 million, marking a year-over-year decrease of 50.97%. This contributed to the annual value of $24.0 million for FY2024, which is 265.14% up from last year.
  • As of Q3 2025, Alnylam Pharmaceuticals' Raw Materials stood at $22.3 million, which was down 50.97% from $22.9 million recorded in Q2 2025.
  • In the past 5 years, Alnylam Pharmaceuticals' Raw Materials registered a high of $65.2 million during Q3 2021, and its lowest value of $14.8 million during Q4 2021.
  • Over the past 5 years, Alnylam Pharmaceuticals' median Raw Materials value was $22.9 million (recorded in 2025), while the average stood at $27.2 million.
  • Its Raw Materials has fluctuated over the past 5 years, first crashed by 7675.07% in 2021, then soared by 5124.71% in 2022.
  • Quarter analysis of 5 years shows Alnylam Pharmaceuticals' Raw Materials stood at $14.8 million in 2021, then surged by 51.25% to $22.3 million in 2022, then increased by 4.62% to $23.3 million in 2023, then increased by 2.65% to $24.0 million in 2024, then fell by 7.15% to $22.3 million in 2025.
  • Its last three reported values are $22.3 million in Q3 2025, $22.9 million for Q2 2025, and $23.4 million during Q1 2025.